Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2173 in Primary IgA Nephropathy
NCT07354932Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Biological product
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2173 in IgA nephropathy (IgAN), sponsored by Hengrui Therapeutics. Started Mar 2026; status: recruiting.
02
Drugs
SHR-2173
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07354932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354932.